Blue Light-Emitting Diode Therapy for Recurrent Vulvovaginal Candidiasis: A Brazilian Report

Abstract Objective We conducted a prospective study with the objective of assessing the effects of antimicrobial blue light (ABL) therapy for recurrent vulvovaginal candidiasis (RVVC) in drug-resistant women. Introduction: RVVC is defined as three or more episodes of candidiasis in a 12-month period. Conventional treatment is complex and often involves long-term or multiple treatments. ABL therapy is a promising treatment option as it is acceptable to women and has with few side effects. Methods Our study enrolled RVVC drug-resistant women, who received ABL through 10 sessions for 20 minutes once a week from January 2023 to January 2024. All women were followed up by 6 months after therapy. Results We included 62 patients. The overall positive response rates were 79% immediately after treatment and 58% after 6 months, respectively. There was an improvement in the symptoms of pruritus, burning, oedema, erythema and leucorrhoea. Conclusion ABL was an effective therapy to be employed in drug-resistant women suffering from RVVC.